{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:36:32Z","timestamp":1769056592255,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515111177"],"award-info":[{"award-number":["2021A1515111177"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515220142"],"award-info":[{"award-number":["2021A1515220142"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012647"],"award-info":[{"award-number":["2023A1515012647"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ygyno.2023.12.019","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T22:50:12Z","timestamp":1703890212000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial"],"prefix":"10.1016","volume":"181","author":[{"given":"Miao-fang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-fang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-pai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-zhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-qiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.12.019_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0010","first-page":"49","article-title":"The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future","volume":"73","author":"Foster","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0015","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the management of peritoneal malignancies","volume":"19","author":"Kepenekian","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0025","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/17425247.2019.1693997","article-title":"Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them","volume":"16","author":"Sugarbaker","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0035","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0045","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1002\/cncr.33163","article-title":"Intraperitoneal chemotherapy: hot, timely, and relevant?","volume":"126","author":"Mackay","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0050","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology","volume":"158","author":"Chambers","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2023.3944","article-title":"Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy","author":"Lee","year":"2023","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0065","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0070","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","author":"Antonio","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2022.12.021","article-title":"Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01)","volume":"170","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0090","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","article-title":"Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma","volume":"33","author":"Lemoine","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/bjc.2014.602","article-title":"Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer","volume":"112","author":"Ansaloni","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0100","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0090-8258(21)00754-X","article-title":"Cisplatin and paclitaxel are associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian cancer","volume":"162","author":"Chambers","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0105","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e3","article-title":"Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study","volume":"30","author":"Lee","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.616264","article-title":"A dose-finding trial for hyperthermic intraperitoneal cisplatin in gynecological cancer patients receiving hyperthermic intraperitoneal chemotherapy","volume":"11","author":"Chan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0115","article-title":"A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer","author":"You","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpainsymman.2007.04.017","article-title":"Evaluation of the symptom representation questionnaire (SRQ) for assessing cancer-related symptoms","volume":"35","author":"Donovan","year":"2008","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0130","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines(R) insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0135","author":"NCI"},{"key":"10.1016\/j.ygyno.2023.12.019_bb0140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2020.05.041","article-title":"A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: a memorial Sloan Kettering cancer center team ovary initiative","volume":"158","author":"Straubhar","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0145","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/rssc.12089","article-title":"Bayesian optimal interval designs for phase I clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"J. R. Stat. Soc.: Ser. C: Appl. Stat."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0155","article-title":"BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies","volume":"4","author":"Lin","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0160","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0175","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","article-title":"Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer","volume":"142","author":"Gouy","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0190","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/JCO.2023.41.16_suppl.5510","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the CHIPOR randomized phase III trial","volume":"41","author":"Classe","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ckj\/sfaa202","article-title":"Anaemia and acute kidney injury: the tip of the iceberg?","volume":"14","author":"Lombardi","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0200","article-title":"Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer","volume":"6","author":"Dellinger","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.019_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.04.029","article-title":"Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer","volume":"282","author":"Dunne","year":"2018","journal-title":"J. Control. Release"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:07:03Z","timestamp":1758773223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823016256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":41,"alternative-id":["S0090825823016256"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}